Is Atara Biotherapeutics, Inc. overvalued or undervalued?

As of 4 May 2021, the valuation grade for Atara Biotherapeutics, Inc. moved from does not qualify to risky. The company is currently overvalued given its negative financial metrics and performance compared to peers. Key ratios include a Price to Book Value of -1.14, an EV to EBITDA of 62.71, and an EV to Sales of 0.51, which indicate significant financial distress and inefficiency.
In comparison to its peers, Atara Biotherapeutics has a P/E ratio of -9.69, while Fusion Pharmaceuticals, Inc. has a P/E of -17.58, and Zevra Therapeutics, Inc. stands at -5.06. The negative returns of Atara Biotherapeutics, particularly a year-to-date decline of 40.80% compared to a 2.44% increase in the S&P 500, further reinforce the notion that the stock is overvalued in the current market environment.